AEMETIS, INC
Business
AEMETIS, INC is an international renewable natural gas and renewable fuels company that operates, acquires, develops, and commercializes technologies to produce low and negative carbon intensity fuels from agricultural products and waste. The company produces ethanol and animal feed co‑products, dairy renewable natural gas (RNG), biodiesel and refined glycerin, sells commercial CO2, and develops sustainable aviation fuel, renewable diesel and carbon capture projects. Its key business segments are California Ethanol, California Dairy RNG, India Biodiesel and development projects at the Riverbank complex. Aemetis markets products into California and Indian fuel, agricultural and industrial channels, injects RNG into utility pipelines, and sells environmental credits.
Summary from filing dated 2025-03-14
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenues | 198 | 268 | 187 | 257 | 212 | |
| Production tax credits | 10 | 0 | — | — | — | |
| Cost of goods sold | 209 | 268 | 185 | 262 | 204 | |
| Gross loss | −768,000 | −580,000 | 2 | −6 | 8 | |
| Selling, general and administrative expenses | 36 | 40 | 39 | 29 | 24 | |
| Operating loss | −37 | −40 | −37 | −34 | −16 | |
| Interest rate expense | 46 | 40 | 33 | 21 | 20 | |
| Debt related fees and amortization expense | 7 | 6 | 7 | 7 | 4 | |
| Accretion and other expenses of Series A preferred units | 8 | 13 | 25 | 10 | 8 | |
| Other income | −3 | −1 | −2 | −14 | 809,000 | |
| Loss before income taxes | −96 | −98 | −100 | −107 | −47 | |
| Income tax benefit | −19 | −11 | −54 | 1 | −128,000 | |
| Net loss | −77 | −88 | −46 | −108 | −47 | |
| Foreign currency translation loss | −990,000 | −695,000 | −219,000 | −1 | −236,000 | |
| Comprehensive loss | −78 | −88 | −47 | −109 | −47 | |
| Basic (in dollars per share) | −1.28 | −1.91 | −1.22 | −3.12 | −1.54 | |
| Diluted (in dollars per share) | −1.28 | −1.91 | −1.22 | −3.12 | −1.54 | |
| Basic (in shares) | 60 | 46 | 38 | 35 | 31 | |
| Diluted (in shares) | 60 | 46 | 38 | 35 | 31 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 5 | 898,000 | 3 | 4 | 8 | |
| Accounts receivable | 484,000 | 2 | 9 | 1 | — | |
| Inventories | 12 | 25 | 18 | 5 | 5 | |
| Prepaid expenses | 2 | 2 | 3 | 4 | 6 | |
| Tax credit sale receivable | 0 | 12 | 0 | — | — | |
| Other current assets | 8 | 2 | 3 | 4 | 644,000 | |
| Total current assets | 27 | 45 | 36 | 18 | 21 | |
| Property, plant and equipment, net | 220 | 199 | 195 | — | — | |
| Operating lease right-of-use assets | 2 | 2 | 2 | 2 | 2 | |
| Other assets | 11 | 13 | 10 | 6 | 3 | |
| Total assets | 260 | 259 | 243 | 207 | 161 | |
| Accounts payable | 23 | 33 | 32 | 26 | 16 | |
| Current portion of long term debt | 279 | 64 | 14 | 12 | 8 | |
| Short term borrowings | 39 | 27 | 23 | 37 | 15 | |
| Other current liabilities | 30 | 20 | 15 | 8 | 6 | |
| Total current liabilities | 371 | 144 | 84 | 88 | 65 | |
| Senior secured notes and revolving notes | 0 | 170 | 176 | 156 | 121 | |
| EB-5 notes | 16 | 22 | 30 | 30 | 33 | |
| Other long term debt | 48 | 56 | 52 | 12 | 12 | |
| Series A preferred units | 127 | 127 | 113 | 116 | 45 | |
| Other long term liabilities | 5 | 5 | 5 | 5 | 2 | |
| Total long term liabilities | 195 | 379 | 376 | 321 | 216 | |
| Common stock, $0.001 par value; 80,000 authorized; 66,189 and 51,139 shares issued and outstanding each period, respectively | 66,000 | 51,000 | 41,000 | 36,000 | 33,000 | |
| Additional paid-in capital | 340 | 305 | 264 | 233 | 205 | |
| Accumulated deficit | −640 | −563 | −475 | −429 | −321 | |
| Accumulated other comprehensive loss | −7 | −6 | −6 | −5 | −4 | |
| Total stockholders' deficit | −307 | −264 | −217 | −202 | −120 | |
| Total liabilities and stockholders' deficit | 260 | 259 | 243 | 207 | 161 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Share-based compensation | 6 | 8 | 8 | 6 | 4 | |
| Stock issued for services | 200,000 | 0 | 1 | 2 | 2 | |
| Depreciation | 10 | 8 | 7 | 6 | 5 | |
| Bad debt expense | 385,000 | 0 | — | 0 | 144,000 | |
| Intangibles and other amortization expense | 46,000 | 46,000 | 72,000 | 46,000 | 46,000 | |
| Debt related fees and amortization expense | 7 | 6 | 7 | 7 | 4 | |
| Gain (Loss) on asset disposals | −4,000 | 4 | 0 | — | — | |
| Gain on debt/liability extinguishment | −1 | −162,000 | 0 | — | — | |
| Loss on impairment of intangibles | 43,000 | 0 | — | — | — | |
| Accounts receivable | 1 | 7 | −7 | 294,000 | 94,000 | |
| Inventories | 13 | −8 | −14 | 360,000 | −2 | |
| Prepaid expenses | 276,000 | 2 | 2 | 2 | −5 | |
| Tax credit sale receivable | 12 | −12 | 0 | — | — | |
| Other assets | −5 | −3 | −2 | −4 | 2 | |
| Accounts payable | −8 | −1 | 14 | 2 | −5 | |
| Accrued interest expense and fees, net of interest paid | 31 | 28 | 24 | 16 | 14 | |
| Other liabilities | 5 | 3 | −2 | −10 | 729,000 | |
| Net cash provided by (used in) operating activities | 3 | −33 | 14 | −23 | −21 | |
| Capital expenditures | −26 | −20 | −33 | −39 | −27 | |
| Grant proceeds received for capital expenditures | 411,000 | 6 | 9 | 8 | 4 | |
| Net cash used in investing activities | −26 | −14 | −24 | −31 | −23 | |
| Proceeds from borrowings | 45 | 19 | 75 | 69 | 0 | |
| Repayments of borrowings | −37 | −5 | −56 | −26 | −56 | |
| Lender debt renewal and waiver fee payments | −1 | −1 | −2 | −1 | — | |
| Payments on Series A preferred financing | −8 | 0 | −30 | 0 | −300,000 | |
| Payments on finance leases | −168,000 | −179,000 | −428,000 | −481,000 | −505,000 | |
| Proceeds from sales of common stock | 28 | 32 | 22 | 12 | 104 | |
| Proceeds from the exercise of stock options | 257,000 | 36,000 | 133,000 | 206,000 | 1 | |
| Net cash provided by financing activities | 26 | 45 | 9 | 54 | 51 | |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | −26,000 | 12,000 | 49,000 | −213,000 | −4,000 | |
| Net change in cash and cash equivalents and restricted cash for period | 4 | −2 | −719,000 | −752,000 | 7 | |
| Cash paid for interest | 14 | 9 | 10 | 20 | 6 | |
| Income taxes paid | 626,000 | 2 | — | — | — | |
| Settlement of Accounts Payable via issuance of common stock | 45,000 | 265,000 | — | — | — | |
| Subordinated debt extension fees added to debt | 1 | 680,000 | 680,000 | 680,000 | 680,000 | |
| Fair value of warrants issued to subordinated debt holders | 740,000 | 916,000 | — | — | — | |
| Lender debt extension, waiver, and other fees added to debt | 2 | 695,000 | 0 | 583,000 | 608,000 | |
| Cumulative capital expenditures in accounts payable and accruals | 8 | 11 | 8 | 15 | 8 | |
| Unpaid capital expenditures in construction financing | 3 | 0 | 0 | 290,000 | 55,000 |